ARTA
LRMR icon

A.R.T. Advisors’s Larimar Therapeutics LRMR Stock Holding History

A.R.T. Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,678
Closed -$22K – 580
2019
Q4 		$22K Buy
+1,678
New +$16K ﹤0.01% 1279
2019
Q3 		– Sell
-2,423
Closed -$35K – 1593
2019
Q2 		$35K Buy
+2,423
New +$64.5K ﹤0.01% 1266
2019
Q1 		– Sell
-3,508
Closed -$208K – 1478
2018
Q4 		$208K Buy
3,508
+1,839
+110% +$182K 0.01% 1054
2018
Q3 		$234K Buy
+1,669
New +$203K 0.01% 1136
2018
Q2 		– Sell
-1,921
Closed -$171K – 1623
2018
Q1 		$171K Buy
1,921
+742
+63% +$62.9K 0.01% 1291
2017
Q4 		$65K Buy
1,179
+155
+15% +$6.99K ﹤0.01% 1285
2017
Q3 		$43K Sell
1,024
-2,110
-67% -$87.7K ﹤0.01% 1265
2017
Q2 		$132K Buy
3,134
+2,239
+250% +$115K 0.01% 1225
2017
Q1 		$50K Sell
895
-1,080
-55% -$53.6K ﹤0.01% 1326
2016
Q4 		$75K Buy
+1,975
New +$80.1K ﹤0.01% 1184
2016
Q3 		– Sell
-5,709
Closed -$410K – 932
2016
Q2 		$410K Sell
5,709
-7,751
-58% -$613K 0.02% 865
2016
Q1 		$1.08M Sell
13,460
-667
-5% -$52.7K 0.05% 552
2015
Q4 		$1.07M Buy
+14,127
New +$2.27M 0.05% 529

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

A.R.T. Advisors's LRMR Position: Q1 2020 in Review

A.R.T. Advisors sold out of Larimar Therapeutics (LRMR) in Q1 2020, closing a stake of 1,678 shares — an estimated $22K sold.

A.R.T. Advisors first reported a position in LRMR in Q4 2015 and held it in 13 quarters. The position peaked at $1.08M in Q1 2016. 42 funds tracked by Wall St. Rank hold LRMR as of Q1 2020.

  • A.R.T. Advisors reported no remaining Larimar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 1,678 Larimar Therapeutics shares in Q1 2020, an estimated $22K.
  • A.R.T. Advisors first reported a position in Larimar Therapeutics in Q4 2015 and held it in 13 quarters.
  • A.R.T. Advisors's Larimar Therapeutics position peaked at $1.08M in Q1 2016.
  • 42 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.